Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society.

Despite the fact that an estimated 60 million people worldwide suffer from neurodegenerative diseases, a population expected to double every 20 years, there are currently no approved disease-modifying therapies or cures available. These diseases devastate patients and their loved ones.

Yumanity is dedicated to protecting the vitality of the mind. Using innovative technology licensed from Susan Lindquist’s laboratory at MIT’s Whitehead Institute, we are working to identify and develop new, disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

LEARN MORE

PRESS RELEASES

October 7, 2019

Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease

VIEW MORE

September 5, 2019

Yumanity Therapeutics Appoints Patricia Allen to its Board of Directors

VIEW MORE



LATEST NEWS

May 1, 2019

Tony Coles joins Bloomberg Baystate Business to discuss Yumanity Therapeutics and the company’s efforts to develop new medicines to treat CNS diseases (segment begins at 44:30)

VIEW MORE

December 10, 2018

A lipid-desaturating enzyme offers a new drug target for Parkinson’s disease

VIEW MORE

November 26, 2017

Tony Coles comments on the environment for raising capital for neurodegenerative disease research

VIEW MORE

ARCHIVE